COSCIENS Biopharma Inc. released its Q2 2026 earnings, revealing a challenging yet pivotal moment for the company.
On August 11, 2026, COSCIENS Biopharma Inc. (CSCI.TO) reported its financial results for the second quarter ending June 30, 2026. The report highlighted a net loss of CA$0.267 per share. While this figure is disappointing, it comes amid strategic initiatives aimed at improving the company’s cash position and operational efficiency. This post-earnings digest will explore the implications of these results for Canadian investors.
Recent earnings trend
Advertisement
COSCIENS Biopharma Inc.
CSCI.TO
CSCI.TO
COSCIENS Biopharma Inc.
WealthAwesomeMarket cap
$8.36M
52W high
$14.80
52W low
$3.30
1W change
-3.67%
Beta
1.89
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CSCI's historical volatility
30-Day Vol
460.3%
Annualized
90-Day Vol
335.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$8.78
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$7.79 | C$1.59 – C$38.13 |
| 60 trading days | C$8.27 | C$0.87 – C$78.13 |
| 90 trading days | C$8.78 | C$0.56 – C$137.37 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: Limited — historical beat/miss data exists for 64 quarter(s), but no upcoming consensus.
Beat estimates in 2 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | -0.2670 | — | — |
| 2026-03-31 | 2026-05-12 | -0.9563 | — | — |
| 2025-09-30 | 2025-11-11 | -0.7885 | — | — |
| 2025-06-30 | 2025-08-12 | -1.1773 | — | — |
| 2025-03-31 | 2025-05-13 | -3.0027 | — | — |
| 2024-09-30 | 2024-11-11 | -2.5268 | — | — |
Advertisement
Investor takeaway: While COSCIENS Biopharma's recent earnings show ongoing challenges, the company's focus on reducing net losses and improving cash flow could signal a strategic shift worth watching. Investors should consider these developments alongside the company's historical performance and current market conditions.
CSCI Reports EPS of -0.267, Continuing to Navigate Financial Challenges
The reported EPS of -0.267 highlights the financial hurdles COSCIENS Biopharma is facing, especially when compared to previous quarters where the company had mixed results in beating estimates.
Bull case
The company has successfully reduced its net loss compared to previous quarters, indicating possible operational improvements. This focus on enhancing cash flow could set COSCIENS up for future growth as it navigates the biopharma landscape.
Bear case
Despite the reduction in net loss, the EPS of -0.267 shows that profitability challenges persist. The stock has seen a significant decline in recent months, raising concerns about investor confidence and the company’s ability to recover in a competitive market.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
